{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"TRESR","nct_id":"NCT04497116","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tresr-nct04497116. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TRESR","arms":[{"description":"Phase 1:\n\nMultiple doses of RP-3500 (camonsertib) for oral administration alone","label":"RP-3500 (camonsertib) alone","type":"EXPERIMENTAL"},{"description":"Phase 2:\n\nExpansion cohorts with RP-3500 (camonsertib)","label":"Expansion cohorts with RP-3500 (camonsertib)","type":"EXPERIMENTAL"},{"description":"Phase 1:\n\nMultiple doses of RP-3500 (camonsertib) for oral administration in combination with talazoparib or gemcitabine","label":"RP-3500 (camonsertib) with Talazoparib or Gemcitabine","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-06-13","type":"ACTUAL"},"conditions":["Advanced Solid Tumor"],"enrollment":{"count":276,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"RP-3500 (camonsertib)","otherNames":[],"type":"DRUG"},{"name":"Talazoparib","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine Injection","otherNames":[],"type":"DRUG"}],"last_update":"2025-10-21","lead_sponsor":"Repare Therapeutics","official_title":"Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2025-06-13","type":"ACTUAL"},"primary_outcomes":[{"measure":"Frequency of Treatment-Related Adverse Event of CTCAE Grade 3 and Above","timeFrame":"Start of treatment to 30 days post last dose, up to 1 year"},{"measure":"Frequency of Dose Limiting Toxicity (DLT)","timeFrame":"Either 21 days or 28 days (1 cycle) from the initiation of the study treatment."}],"references":[{"citation":"Fontana E, Rosen E, Lee EK, Hojgaard M, Mettu NB, Lheureux S, Carneiro BA, Cote GM, Carter L, Plummer R, Mahalingam D, Fretland AJ, Schonhoft JD, Silverman IM, Wainszelbaum M, Xu Y, Ulanet D, Koehler M, Yap TA. Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study). J Natl Cancer Inst. 2024 Sep 1;116(9):1439-1449. doi: 10.1093/jnci/djae098.","pmid":"38710487","type":"DERIVED"},{"citation":"Yap TA, Fontana E, Lee EK, Spigel DR, Hojgaard M, Lheureux S, Mettu NB, Carneiro BA, Carter L, Plummer R, Cote GM, Meric-Bernstam F, O'Connell J, Schonhoft JD, Wainszelbaum M, Fretland AJ, Manley P, Xu Y, Ulanet D, Rimkunas V, Zinda M, Koehler M, Silverman IM, Reis-Filho JS, Rosen E. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med. 2023 Jun;29(6):1400-1411. doi: 10.1038/s41591-023-02399-0. Epub 2023 Jun 5.","pmid":"37277454","type":"DERIVED"}],"start_date":{"date":"2020-07-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of RP-3500, Camonsertib, in Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT04497116"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tresr-nct04497116"}